3-Bromomethcathinone
 | |
| Clinical data | |
|---|---|
| Other names | 3-BMC; 3-Br-MC; 3′-Bromo-2-(methylamino)propanophenone; 3-BMAP |
| Routes of administration | Oral |
| Drug class | Stimulant; Serotonin–norepinephrine–dopamine releasing agent (SNDRA) |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H12BrNO |
| Molar mass | 242.116 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Bromomethcathinone (3-BMC) is a stimulant designer drug and monoamine releasing agent of the cathinone family.[1][2][3][4] It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA), with EC50 values for induction of monoamine release of 136–137 nM for serotonin, 25 nM for norepinephrine, and 21–28 nM for dopamine in rat brain synaptosomes.[2][3][4] The drug produces hyperlocomotion in rodents comparably to but with slightly lower potency than methcathinone.[5][6] The chemical synthesis of 3-BMC has been described.[6] 3-BMC was first described in the scientific literature by 2002.[7][6] It emerged as a novel designer drug in Israel and Germany and elsewhere in 2009.[1]
See also
[edit]- Substituted cathinone
- 3-Fluoromethcathinone (3-FMC)
- 3-Chloromethcathinone (3-CMC; clophedrone)
- 3-Methylmethcathinone (3-MMC; metaphedrone)
- 4-Bromomethcathinone (4-BMC; brephedrone)
References
[edit]- 1 2 Meyer MR, Vollmar C, Schwaninger AE, Wolf E, Maurer HH (February 2012). "New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine". Journal of Mass Spectrometry. 47 (2): 253–262. Bibcode:2012JMSp...47..253M. doi:10.1002/jms.2960. PMID 22359337.
- 1 2 Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology. 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
- 1 2 Shalabi AR (14 December 2017). Structure-Activity Relationship Studies of Bupropion and Related 3-Substituted Methcathinone Analogues at Monoamine Transporters. VCU Scholars Compass (Doctor of Philosophy thesis). doi:10.25772/M4E1-3549.
- 1 2 Walther D, Shalabi AR, Baumann MH, Glennon RA (January 2019). "Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents". ACS Chemical Neuroscience. 10 (1): 740–745. doi:10.1021/acschemneuro.8b00524. PMC 8269283. PMID 30354055.
- ↑ Glennon RA, Dukat M (2017). "Structure-Activity Relationships of Synthetic Cathinones". Current Topics in Behavioral Neurosciences. 32. Cham: 19–47. doi:10.1007/7854_2016_41. ISBN 978-3-319-52442-9. PMC 5818155. PMID 27830576.
In a locomotor assay in rats, 3-bromomethcathinone (21; Figure 5) produced hyperlocomotion at doses of 7.5 and 10 mg/kg comparable to that produced by methcathinone at 5 mg/kg, whereas 4-bromomethcathinone (22), now termed brephedrone or 4-BMC, was inactive at these doses (Foley and Cozzi, 2003).
{{cite journal}}: CS1 maint: periodical has ISBN (link) - 1 2 3 Foley KF, Cozzi NV (2003). "Novel aminopropiophenones as potential antidepressants" (PDF). Drug Development Research. 60 (4): 252–260. doi:10.1002/ddr.10297. ISSN 0272-4391.
- ↑ Foley KF, Cozzi NV (June 2002). "Inhibition of transport function and desipramine binding at the human noradrenaline transporter by N-ethylmaleimide and protection by substrate analogs" (PDF). Naunyn-Schmiedeberg's Archives of Pharmacology. 365 (6): 457–461. doi:10.1007/s00210-002-0532-3. PMID 12070759.
External links
[edit] | This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information. |